Platinum-Resistant Ovarian Cance research hub

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib and ZN-c3 Monotherapy in Subjects with Platinum-resistant Ovarian Cancer.

This study is testing different ways to use a new drug called azenosertib (also known as ZN-c3) for women with ovarian cancer that has become resistant to common treatments. It aims to find the safest and most effective dose, whether used alone or with another drug called niraparib.